Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)

NCT02563002 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

307

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Carcinoma

Interventions

DRUG: mFOLFOX6
DRUG: FOLFIRI
BIOLOGICAL: Pembrolizumab
BIOLOGICAL: Bevacizumab
BIOLOGICAL: Cetuximab

Sponsor

Merck Sharp & Dohme LLC